Impact of Human Blood Serum From Critically Ill Patients on Human Colon Neuronal Networks.
NCT ID: NCT02706314
Last Updated: 2019-04-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
61 participants
OBSERVATIONAL
2016-03-31
2019-04-16
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Diagnostic tests to determine CIP during the course of critical illness are available through nerve conduction studies. Further research is needed to find diagnostic tools to identify patients who are on high risk to develop CIP, which could encourage the evolution of new therapeutic strategies for CIP patients.
The aims of the study are:
1. An early detection of changes in intramural neuronal networks of human colon samples induced by human blood serum from critically ill patients in order to predict the development of CIP
2. The comparison of different diagnostic tests to diagnose and monitor CIP during the course of critical illness (neurologic examination versus nerve conduction study versus neuromyosonography)
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Neurological Blood-based Biomarkers and Cognitive Disorders in Critically Ill Survivors.
NCT05953311
Dysregulated CNS Inflammation After Acute Brain Injury
NCT03287557
Development and Validation of a Prognostic Model for Neurocritical Patients Using Multimodal Brain Monitoring
NCT07115459
Survival and Predictive Factors of Clinical Outcome in Patients With Acquired Brain Injury
NCT05968911
Analysis of Selective Cerebrovascular Distribution With FDCT in the Angiosuite
NCT03916133
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The inclusion of patients will be started if written informed consent was obtained from all participants or their representatives (if direct consent could not be obtained).
The aim of the study is a prediction or an earlier detection of CIP in critically ill patients before nerve conduction studies are able to diagnose CIP. We hypothesize that upregulated circulating neurotoxic factors in human serum of critically ill patients cause neuronal damage and play an important role in the pathogenesis of CIP. Time from upregulation of neurotoxic factors to the clinical appearance of neuronal damage (CIP) is unknown.
An experimental part of the study aims at establishing enteric neuronal networks as functional bioassays for the qualitative detection of neurotoxic humoral factors. Human colon samples will be exposed to the serum of critically ill patients with and without CIP in an organ bath (100% serum) under standardized physiologic conditions. Alterations to neuronal functions (contractions, spontaneous activity) will be studied between serum from patients with CIP, without CIP and serum probes from healthy volunteers (without critical illness).
In a clinical part of the study critically ill patients with and without CIP (detected by nerve conduction studies as the gold standard for the diagnosis of CIP) will be examined by neurologic examination, nerve conduction study and neuromyosonography of peripheral nerves. The incidence, the extent and the time from the beginning of critical illness to the clinical appearance of nerval alterations will be compared between the 3 diagnostic tests.
From all patients basic demographic data, illness severity scores (APACHE-II, SOFA) laboratory results, pre-morbidity data and clinical outcome for the study cohort will be recorded. At day 3 and 10 patients will be examined by neurologic examination, nerve conduction study, neuromyosonography and laboratory tests (inflammation, coagulation, organ function, blood parameters including TNF-alpha, IL-6, S100b, oxidative stress markers, neurofilaments, C-type natriuretic peptide).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Critically ill patients with CIP
Critically ill patients with a Sequential Organ Failure Assessment (SOFA)-Score \>7 with CIP
No interventions assigned to this group
Critically ill patients without CIP
Critically ill patients with a Sequential Organ Failure Assessment (SOFA)-Score \>7 without CIP
No interventions assigned to this group
Healthy volunteers
Healthy volunteers with neither critical illness nor CIP
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Informed consent by patient or legal proxy
Exclusion Criteria
* High-dose glucocorticosteroid therapy (\> 300 mg Hydrocortisone/die)
* Age \< 18
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Rostock
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr. Johannes Ehler, MD
Dr. med. Johannes Ehler
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Intensive Care Unit PIT 1 and 2, University hospital Rostock
Rostock, , Germany
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Klawitter F, Laukien F, Fischer DC, Rahn A, Porath K, Danckert L, Bajorat R, Walter U, Patejdl R, Ehler J. Longitudinal Assessment of Blood-Based Inflammatory, Neuromuscular, and Neurovascular Biomarker Profiles in Intensive Care Unit-Acquired Weakness: A Prospective Single-Center Cohort Study. Neurocrit Care. 2025 Feb;42(1):118-130. doi: 10.1007/s12028-024-02050-x. Epub 2024 Jul 9.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A 2016-0016
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.